He is also a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on the molecular drivers underlying soft tissue sarcoma, a cancer of connective tissues that occurs throughout the body.

Dr. Pollock’s current studies include the role of MDM2 in dedifferentiated liposcaroma, circulating miRNA in soft tissue sarcoma and genetic determinants of desmoid tumor progression. These investigations are supported by a comprehensive soft tissue tumor acquisition program in collaboration with Hans Iwenofu, MD, of the Department of Pathology and Thomas Scharschmidt, MD, and Joel Mayerson, MD, of the Department of Orthopaedic Surgery. The retrieved tissues are used to create cell lines and cell strains. These tissues are also implanted in vivo to establish small animal models that support preclinical therapy investigations.